-
AzurRx Launches Trial Testing MS1819-SD Combined with PERT for Cystic Fibrosis
AzurRx BioPharma has initiated a Phase 2 clinical trial testing MS1819-SD combined with PERT for CF patients with exocrine pancreatic insufficiency. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.